These observations suggest that EHF may be a new transcription factor for HER2 and HER3 in thyroid cancer by binding to a functional EBS within their promoter, and plays its oncogenic function by activating HER family of receptor tyrosine kinases, contributing to thyroid tumorigenesis. This evidence concerns the gene NTRK1 and thyroid gland carcinoma.